Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2007-02-20
2007-02-20
Wehbe′, Anne M. (Department: 1633)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S325000, C435S320100
Reexamination Certificate
active
09484964
ABSTRACT:
Disclosed are compositions comprising a novel cell-death protecting protein, sentrin-1, and the gene which encodes it. Also disclosed are methods of making and using sentrin polypeptides and nucleic acid segments in various diagnostic and pharmaceutical applications. In a preferred embodiment, overexpression of sentrin-1 confers protection against both anti-Fas/APO-1 and TNF-induced apoptosis.
REFERENCES:
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4757011 (1988-07-01), Chaleff et al.
patent: 4769061 (1988-09-01), Comai
patent: 4940835 (1990-07-01), Shah et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 4971908 (1990-11-01), Kishore et al.
patent: 5176995 (1993-01-01), Sninsky et al.
patent: 5384253 (1995-01-01), Krzyzek et al.
patent: WO 95/31544 (1995-11-01), None
Orkin et. al.; Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
Lieberthal et. al.; Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury, 1996, Invited Review : F477-F488.
Lavin et. al.; Role of protein kinase activity in apoptosis, 1996, Experiential 52:979-994.
Marshall; Gene Therapy's Growing Pains, 1995, Science, vol. 269: 1050-1055.
Verma et. al.; Gene therapy- promises, problems and prospects, 1997, Nature vol. 389: 239-242.
Boddy et al., “PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia”,Oncogene, 13:971-982, 1996.
Cenciaelli et al., “T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation,”J. Biol. Chem., 271(15):8709-8713, 1996.
Chinnaiyan et al., “FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis,”Cell, 81:505-512, 1995.
Chinnaiyan et al., “FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis,”J. Biol. Chem., 271(9):4961-4965, 1996.
Chu et al., “A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis,”Proc. Natl. Acad. Sci. USA, 92:11894-11898, 1995.
Coux et al., “Structure and functions fo the 20S and 26S proteasomes,”Annu. Rev. Biochem., 65:801-847, 1996.
Darnay et al., “Identification of a protein kinase associated with cytoplasmic domain of the p60 tumor necrosis factor receptor,”J. Biol. Chem., 269(32):20299-20304, 1994.
Finley et al., “Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant,”Mol. Cell. Biol., 14(8):5501-5509, 1994.
Görlich et al., “Nucleocytoplasmic transport,”Science, 271:1513-1518, 1996.
Göttlicher et al., “Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor,”Steroids, 61:257-262, 1996.
Hateboer et al., “mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect,”J. Biol. Chem., 271(42):25906-25911, 1996.
Hsu et al., “TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways,”Cell, 84:299-308, 1996a.
Hsu et al. “TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1,”Immunity, 4:387-396, 1996b.
Kamitani et al., “Characterization of NEED8, a developmentally down-regulated ubiquitin,”J. Biol. Chem., 272(45):28557-28562, 1997b.
Kamitani et al., “Preferenctial modification of nuclear proteins by a novel ubiquitin-like molecule,”J. Biol. Chem., 272(22):14001-14004, 1997.
Kho et al., “Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A,”J. Biol. Chem., 272(6):3845-3851, 1997.
Kischkel et al., “Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor,”EMBO J., 14(22):5579-5588, 1995.
Mannen et al., “Cloning and expression of human homolog HSMT3 to yeast SMT3 suppressor of MIF2 mutations in a centromere protein gene,”Biochem. Biophy. Res. Comm., 222:178-180, 1996.
Muzio et al., “FLICE, novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex,”Cell, 85:817-827, 1996.
Nuber et al., “Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5,”J. Biol. Chem., 271(5):2795-2800, 1996.
Saitoh et al., “RanBP2 associates with Ubc9p and a modified form of RanGAP1,”Proc. Natl. Acad. Sci. USA., 94:3736-3741, 1997.
Stanger et al., “RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death,”Cell, 81:513-523, 1995.
Takayama et al., “Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity,”Cell, 80:279-284, 1995.
Wang et al., “Molecular cloning of a cNDA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9,”J. Biol. Chem., 271(40):24811-24816, 1996.
Ayala et al., “Mendelain Genetics,” In:Modern Genetics, 2nd Edition, Menlo Park, California, Benjamin/Cummings Publishing Co., Inc., Chapter 2, p. 44, 1984.
Darnell et al., In:Molecular Cell Biology, Scientific American Books, New York, pp. 77-80 and 248-257, 1986.
Database GenBank on STN. US National Library of Medicine (Bethesda, MD, USA). GenBank Accession No. H98111, Hellier et al., “The WashU-Merck EST Project,” yx09d11.slHomo sapienscDNA clone 261237 3′. Dec. 12, 1995.
Database GenBank on STN. US National Library of Medicine (Bethesda, MD, USA). GenBank Accession No. H24103, Hellier et al., “The WashU-Merck EST Project,” ym50b07.rlHomo sapienscDNA clone 51818 5′. Jul. 6, 1995.
International Search Report dated Mar. 11, 1998 (PCT/US97/20344)(UTFH:238P).
Shen et al., “UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins,”Genomics, 36(2):271-279, 1996.
Matunis et al., “A novel ubiquitin-like modification modulates the partitioning of the ran-GTpase-activating protein Ran GAP1 between the Cytosol and the nuclear pore complex,”J. Cell Biol., 135(6):1457-1470, 1996.
Okura et al., “Protection against Fas/APO-1 and tumor necrosis factor-mediated cell death by a novel protein, Sentrin,”J. Immunol., 157(10):4277-4281, 1996.
Shen et al., “Associations of UBE21 with RAD52, UBL1, p. 53, and RAD51 proteins in a yeast two-hybrid systems,”Genomics, 37:183-186, 1996.
Board of Regents the University of Texas System
Fulbright & Jaworski LLP
Wehbe′ Anne M.
LandOfFree
Compositions and uses for a novel cell-death-protecting protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and uses for a novel cell-death-protecting protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and uses for a novel cell-death-protecting protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3870707